I-Mab Current Cash

The latest current cash for IMAB is $170M as of June 2025. That compares with $150M in the prior-year period — up 8.8% year over year. Investors often review this figure alongside I-Mab's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMAB's current cash moved from $150M to $170M — a 8.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in I-Mab's operating scale or balance-sheet position.

A current cash figure of $170M for IMAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting IMAB's current cash ($170M), review year-over-year change from $150M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack I-Mab's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.